Clinical Trial Update: A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine. [Phase 2]

View source ↗

Summary

Pfizer conducted a Phase 2 study to evaluate a Clostridioides difficile vaccine in healthy adults aged 50 to 85 who received three doses; the trial is completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Snippet

Sponsor: Pfizer | Conditions: Clostridium Difficile Associated Disease | Phase 2 | Status: COMPLETED | Results posted: 2017-01-30